Monitor the pricing and closing of the equity offering; if the offering closes, the repurchase will remove a large holder overhang. The net dilution impact depends on the offering size relative to the repurchase. Watch for Q1 2026 earnings (due May) for precise cash position.
Price Chart
Executive Summary
Aura Biosciences announced a stock repurchase agreement with Matrix Capital to buy back up to 6.9M shares at $5.64/share, contingent on the closing of a concurrent equity offering. The company also reported preliminary cash of ~$114.7M as of March 31, 2026. The repurchase removes a 10.8% holder overhang but is funded by new dilution, creating offsetting effects.
Key Financial Metrics
Key Facts
- Entered repurchase agreement with Matrix Capital to buy back up to 6,922,870 shares at $5.64 per share, representing all shares held by Matrix (10.8% stake).
- Repurchase is conditioned on closing of underwritten equity offering announced May 4, 2026, and will be funded from net offering proceeds exceeding $200M.
- Preliminary cash, cash equivalents and marketable securities were approximately $114.7M as of March 31, 2026 (unaudited), down from $144.2M at Dec 31, 2025.
- The repurchase was approved by the audit committee of the board; shares repurchased will become authorized but unissued shares.
- Matrix held approximately 10.8% of outstanding common stock prior to the offering and repurchase.
Financial Impact
Repurchase value estimated at ~$39M (6.9M shares × $5.64), but funded from offering proceeds; net dilution from offering partially offset. Preliminary cash $114.7M indicates Q1 2026 cash burn of ~$30M.
Risk Factors
- Equity offering may not close on favorable terms or at all, preventing the repurchase.
- Cash burn continues, with Q1 2026 spending ~$30M; runway into Q1 2027 may be shortened if offering raises less than expected.
- Dilution from offering offsets the positive impact of the repurchase; net effect on stock price is uncertain.
- CEO transition and clinical trial execution risks remain.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-204049 |
| Document: 0001193125-26-204049-index-headers.html | 0001193125-26-204049 |
| Document: 0001193125-26-204049-index.html | 0001193125-26-204049 |
| Document: 0001193125-26-204049.txt | 0001193125-26-204049 |
| 8-K Data (Synthetic) | 0001193125-26-204049 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 4w ago | Institutional Cluster | $6.45 $6.56 | ▲ +1.71% | ▲ +2.27% | $6.16 (−4.50%) |
Aug 21, 2026 9w ago | EFFECT | $7.80 $6.36 | ▲ +18.46% | ▲ +17.94% | $6.16 (+21.03%) |
Aug 11, 2026 11w ago | 8-K | $8.04 $7.20 | ▲ +10.45% | ▲ +9.39% | $6.16 (+23.38%) |
Aug 11, 2026 11w ago | Press Release | $8.04 $7.20 | ▲ +10.45% | ▲ +9.39% | $6.16 (+23.38%) |
Jul 8, 2026 15w ago | 8-K | $7.25 $7.18 | ▼ −0.97% | ▼ −4.24% | $6.16 (−15.03%) |
May 19, 2026 22w ago | Press Release | $7.47 $6.34 | ▼ −15.13% | ▼ −15.87% | $6.16 (−17.54%) |
May 5, 2026 24w ago | 8-K | $8.29 $6.88 | ▲ +17.01% | ▲ +19.79% | $6.16 (+25.69%) |
May 5, 2026 24w ago | Press Release | $8.29 $6.88 | ▲ +17.01% | ▲ +19.79% | $6.16 (+25.69%) |
May 4, 2026 25w ago | 8-K | $8.90 $6.90 | ▼ −22.47% | ▼ −27.43% | $6.16 (−30.79%) |
May 4, 2026 25w ago | Press Release | $8.35 $7.19 | ▲ +13.89% | ▲ +19.54% | $6.16 (+26.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers